Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01039155 · ClinicalTrials.gov registry record · Phase 1
Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy
A Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Adult Solid Neoplasm, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT01039155: Completed Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Adult Solid Neoplasm, sponsored by National Cancer Institute (NCI).
NCT01039155 is a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Adult Solid Neoplasm that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 41 participants, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01039155, a Phase 1 study of Hematopoietic and Lymphoid Cell Neoplasm and Adult Solid Neoplasm, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I clinical trial studies the side effects and the best dose of azacitidine and oxaliplatin in treating patients with advanced cancers that do not respond to treatment or have returned after any platinum therapy. Azacitidine is designed to activate (turn on) certain genes in cancer cells whose job is to fight tumors. Oxaliplatin is designed to block the growth and spread of new cancer cells, eventually destroying them, by damaging their deoxyribonucleic acid (DNA). Giving azacitidine with oxaliplatin may kill more cancer cells and may also reverse resistance to platinum-based drugs.
Conditions Studied
Interventions
- DRUG Oxaliplatin
- DRUG Azacitidine
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-12 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
What the finished NCT01039155 record still lists
NCT01039155 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 953-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Oxaliplatin is the first listed.
NCT01039155 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01039155 about?
NCT01039155 is a clinical study titled "Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy". This phase I clinical trial studies the side effects and the best dose of azacitidine and oxaliplatin in treating patients with advanced cancers that do not respond to treatment or have returned after any platinum therapy. Azacitidine is designed to activate (turn on) certain genes in cancer cells w...
What is the current status of trial NCT01039155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2009-12. Estimated completion is 2015-07.
What conditions does trial NCT01039155 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Adult Solid Neoplasm.
What interventions are being tested in trial NCT01039155?
The interventions under investigation include: Oxaliplatin (DRUG), Azacitidine (DRUG), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT01039155?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01039155 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphoid Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01039155's enrollment target sits among peer trials
41 66th of 104 higher than 38 of 104 other Hematopoietic and Lymphoid Cell Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematopoietic and Lymphoid Cell Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
RECRUITING · Phase 1
-
Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer Patients
RECRUITING · Phase 1
-
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
RECRUITING · Phase 1
-
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia